Wei-An Song

Wei-An Song

Auto-generated profile, based on publicly available information

Wei-An Song

Department of Thoracic Surgery, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
WSWei-An Song
Wei-An Song
NZNai-Kang Zhou
Nai-Kang Zhou
WWWei Wang
Wei Wang
XCXiang-Yang Chu
Xiang-Yang Chu
CLChao-Yang Liang
Chao-Yang Liang
WDWei-Min Dai
Wei-Min Dai
In 2006, Burdett et al.1 x 1 Burdett, S, Stewart, LA, and Rydzewska, L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006; 1: 611–621 Abstract | Full Text | Full Text PDF | PubMed | Google Scholar See all References published a systematic review to clarify the effectiveness of neoadjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). In their review, they conducted a meta-analysis (quantitative assessment) and discovered a survival benefit of neoadjuvant chemotherapy in operable NSCLC patients. Their results strengthened neoadjuvant chemotherapy as a strategic treatment choice for operable NSCLC patients for the sake of long-time survival. Nevertheless, the data supporting their conclusion seemed a little weak in respect that there were only seven eligible trials included in that analysis and that most of those included trials were small-scale ones.

28 February 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
WSWeian Song
Weian Song
SDShouyin Di
Shouyin Di
JLJunqiang Liu
Junqiang Liu
BFBoshi Fan
Boshi Fan
JZJiahua Zhao
Jiahua Zhao
TGTaiqian Gong
Taiqian Gong
Background: Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non‐small cell lung cancer (NSCLC). There is a lack of high‐level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literature.Methods: A retrospective analysis of patients who underwent salvage surgery in our center between January 2016 and June 2019 for advanced NSCLC after targeted therapy was performed.Results: A total number of nine patients were identified, including five males and four females, with a median age of 56 years (range, 40–65 years), all diagnosed with lung adenocarcinoma stage IIIa–IVb. All patients had received targeted therapy according to individual positive mutation of driver gene(s). Salvage surgery was performed for tumor recurrence or residual tumor after a duration of 2–46 months of targeted therapy. A negative surgical margin was achieved in all cases. Postoperative complication rate was 11.1% (1/9). All patients were alive at the time of this analysis and two patients had disease progression. After a median follow‐up of 17 months (range: 5–44 months), the median event‐free survival and postoperative survival was 14 months (range: 2–44 months) and 17 months (range: 5–44 months) respectively.Conclusions: Salvage surgery may be a feasible and promising therapeutic option for tumor recurrence or residual tumor in advanced NSCLC in selective patients after targeted therapy.Key points: Salvage surgery is feasible in selected patients with advanced NSCLC and provides promising survival outcomes after targeted therapy failure. Salvage surgery provides precise molecular and pathological information which is most important for subsequent therapy.

1 October 2011
Verified
Journal Article
Closed access
WSWei-An Song
Wei-An Song
XLXi Liu
Xi Liu
XTXiao-Dong Tian
Xiao-Dong Tian
WWWei Wang
Wei Wang
CLChao-Yang Liang
Chao-Yang Liang
NZNai-Kang Zhou
Nai-Kang Zhou

1 July 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
WSWei-An Song
Wei-An Song
NZNai-Kang Zhou
Nai-Kang Zhou
XTXiao-Dong Tian
Xiao-Dong Tian
We read with great interest the recent article in Journal of Thoracic Oncology by Shimizu et al., Shimizu K Yoshida J Kakegawa S et al. Primary thymic mucosa-associated lymphoid tissue lymphoma: diagnostic tips. J Thorac Oncol. 2010; 5 : 117-121 Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar who proposed a diagnosis flow chart (Figure 3) for thymic mucosa-associated lymphoid tissue (MALT) lymphoma. The diagnosis flow chart is creative and valuable and presents a clear path of identifying thymic MALT lymphoma. We extend the topic by stressing the role of surgery in the management of this rare disease.

20 October 2006
Verified
Journal Article
Closed access
WSWeian Song
Weian Song
WWWei Wang
Wei Wang
LSLiqun Shang
Liqun Shang
FWFeng Wen
Feng Wen
JLJun Li
Jun Li

20 February 2004
Verified
Journal Article
Closed access
WSWeian Song
Weian Song
HLHui Li
Hui Li
HWHuasheng Wang
Huasheng Wang
WZWeidong Zhang
Weidong Zhang
XZXiaogang Zhao
Xiaogang Zhao